User menu

A Phase-ii Trial of Ci-921 in Advanced Malignancies

Bibliographic reference Sklarin, NT. ; Robert, Francois ; Wiernik, PH. ; Grove, WR. ; Benson, L. ; et. al. A Phase-ii Trial of Ci-921 in Advanced Malignancies. In: Investigational New Drugs : the journal of new anti-cancer agents, Vol. 10, no. 4, p. 309-312 (1992)
Permanent URL http://hdl.handle.net/2078.1/49937
  1. Grove WR, Fortner CL, Wiernik PH: Review of amsacrine, an investigational antineoplastic agent. Clin Pharm 1:320?326, 1982
  2. Grove WR, Delap LW, Grillo-Lopez AJ: CI-921: An analog of amsacrine with experimental activity against solid tumors. Invest New Drugs 4:113?118, 1986
  3. Baguley BC, Denny WA, Atwell GJ, Finlay GJ, Rewcastle GW, Twigden SJ, Wilson WR: Synthesis, antitumor activity, and DNA binding properties of a new derivative of amsacrine, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino) phenylamino]-4-acridinecarboxamide. Cancer Res 44:3245?3251, 1984
  4. Robert F, Mignucci M, Grove WR, Javier J, Asmar S, GrilloLopez AJ: Phase I study of CI-921: Single dose schedule. Proc Am Soc Clin Oncol 6:26, 1987
  5. Grove WR, Grillo-Lopez AJ, Robert F, Harvey V, Leiby J, Javier J, Hardy J, Grever M: Optimizing therapeutic potential of Phase I studies: coordination of three worldwide studies of CI-921. Proc Eur Cong Clin Oncol 4:287, 1987
  6. Hardy JR, Harvey VJ, Paxton J, Evans P, Smith S, Grove WR, Grillo AJ, Baguley BC: Phase I trial of the amsacrine analogue 9-[[2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino]-N,5-dimethyl-4-acridinecarboxamide, (CI-921). Cancer Res 48:6593?6596, 1988
  7. Harvey VJ, Hardy JR, Smith S, Grove W, Baguley BC: Phase II study of the Amsacrine analogue CI-921 (NSC 343499) non-small cell lung cancer. Eur J Cancer 27:1617?1620, 1991
  8. Sklarin N, Wiernik P, Mittelman A, Maroun J, Stewart J, Robert F, Doroshow J, Akman S, Rosen P, Gota C, Jolivet J, Belanger K, DeConti R, Robert N, Velez-Garcia E, Bergsagel D, Panasci L, van der Merwe A, Leiby J, Grove WR, Hawkins E, Kowal C: A Phase II evaluation of CI-921 in patients with solid tumors. Proc Am Soc Clin Oncol 9:285, 1990
  9. Simon R: How large should a Phase II trial of a new drug be? Cancer Treat Rep 71:1079?1085, 1987